Bluebird's one-shot gene therapy for beta thalassemia officially secures EMA backing — approval expected in the second quarter
Days after two charities abruptly preannounced that the EMA had endorsed the approval of bluebird bio’s keenly anticipated gene-replacement therapy LentiGlobin, for beta thalassemia …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
